Status:
TERMINATED
Effect of Milnacipran on Pain Processing and Functional Magnetic Resonance Imaging (fMRI) Activation Patterns in Patients With Fibromyalgia
Lead Sponsor:
Forest Laboratories
Conditions:
Fibromyalgia
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the effect of milnacipran on how the brain processes pain in patients with fibromyalgia and to assess the relationship between this effect and brain activation...
Eligibility Criteria
Inclusion
- Diagnosis of fibromyalgia defined by 1990 American College of Rheumatology (ACR) criteria
- Visual analog pain score between 40 and 90 mm
- Right-hand dominance
Exclusion
- Suicidal risk
- Substance Abuse
- Pulmonary dysfunction
- Renal impairment
- Active cardiac disease
- Autoimmune disease
- Uncontrolled narrow-angle glaucoma
- Active liver disease
- Cancer
- Active peptic ulcer disease or a history of inflammatory bowel disease or celiac sprue
- Unstable endocrine disease
- Prostatic enlargement
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT00793520
Start Date
November 1 2008
Last Update
July 1 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Forest Investigative Site
Ann Arbor, Michigan, United States, 48106